CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42 (Q35580179)

9 August 2017

1 reference

reason for preferred rank

title

CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42 (English)

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

30 March 2024

CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14608585

30 March 2024

0 references

Kaj Blennow

1 reference

9 August 2017

Magnus Sjögren

1 reference

9 August 2017

Niels Andreasen

1 reference

9 August 2017

language of work or name

1 reference

1 October 2003

1 reference

full work available at URL

9 August 2017

http://www.tandfonline.com/doi/pdf/10.1080/15622970310029912

1 reference

DOI

https://api.crossref.org/works/10.1080/15622970310029912

World Journal of Biological Psychiatry

30 March 2024

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

147-155

1 reference

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal fluid tau protein as a potential diagnostic marker in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Microtubule formation and neurite growth in cerebellar macroneurons which develop in vitro: evidence for the involvement of the microtubule-associated proteins, MAP-1a, HMW-MAP2 and Tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Comparison of Neuropathologic Criteria for the Diagnosis of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Tau protein and the neurofibrillary pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Increased cerebrospinal fluid cAMP levels in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Increased tau protein level in postmortem cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Tau Protein in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970310029912

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Increased cerebrospinal fluid tau in patients with Alzheimer's disease

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process

30 March 2024

1 reference

https://api.crossref.org/works/10.1080/15622970310029912

30 March 2024

Identifiers

DOI

1 reference

9 August 2017

1 reference